[
    [
        {
            "time": "2023-11-15",
            "original_text": "【浙商医药|周报】短期调整下，哪些赛道安全边际高、成长属性强？",
            "features": {
                "keywords": [
                    "医药",
                    "短期调整",
                    "安全边际",
                    "成长属性"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【浙商医药|周报】短期调整下，哪些赛道安全边际高、成长属性强？",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "药明康德(02359)拟认购Pontifax (Cayman) VI L.P. 500万美元基金份额",
            "features": {
                "keywords": [
                    "药明康德",
                    "认购",
                    "基金",
                    "500万美元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)拟认购Pontifax (Cayman) VI L.P. 500万美元基金份额",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "药明康德(02359)将回购26.62万股限制性A股股票",
            "features": {
                "keywords": [
                    "药明康德",
                    "回购",
                    "限制性股票"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)将回购26.62万股限制性A股股票",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "药明康德(02359)将回购注销约6.98万股限制性A股股票",
            "features": {
                "keywords": [
                    "药明康德",
                    "回购注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)将回购注销约6.98万股限制性A股股票",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "药明康德(603259.SH)拟认购Pontifax基金份额500万美元",
            "features": {
                "keywords": [
                    "药明康德",
                    "认购",
                    "基金",
                    "500万美元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(603259.SH)拟认购Pontifax基金份额500万美元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
            "features": {
                "keywords": [
                    "医药生物",
                    "冠脉支架",
                    "国采",
                    "头部企业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "医药生物行业周报：三季报密集披露 浙江率先公布新冠疫苗价格",
            "features": {
                "keywords": [
                    "医药生物",
                    "三季报",
                    "新冠疫苗",
                    "浙江"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：三季报密集披露 浙江率先公布新冠疫苗价格",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "【异动股】药明康德(02359-HK)跌3.5%",
            "features": {
                "keywords": [
                    "药明康德",
                    "异动股",
                    "下跌"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【异动股】药明康德(02359-HK)跌3.5%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
            "features": {
                "keywords": [
                    "医药生物",
                    "流感",
                    "肺炎",
                    "疫苗",
                    "三季报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
            "features": {
                "keywords": [
                    "医药生物",
                    "冠脉支架",
                    "集采",
                    "高耗投资"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-11-15",
            "original_text": "港股IPO|“药明系”第三家，药明巨诺通过港交所聆讯",
            "features": {
                "keywords": [
                    "港股IPO",
                    "药明系",
                    "药明巨诺",
                    "聆讯"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "港股IPO|“药明系”第三家，药明巨诺通过港交所聆讯",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]